COLLAGEN-RELATED PEPTIDES AND USES THEREOF AND HEMOSTATIC FOAM SUBSTRATES

• US 20100021527A1
• Filed: 01/30/2009
• Published: 01/28/2010
• Est. Priority Date: 07/25/2008
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: John, Thoppil Mathew, Yang, Chunlin, Matalenas, Thomas
• Application Number:
  US12/362,908
• Publication Number:
  US 20100021527A1
• Time in Patent Office: Days
• US Class Current: 424/445
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61L 24/0036 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 24/046 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043 takes precedence
• CPC Class Codes: A61L 24/10 Polypeptides; Proteins A61L24/043 takes precedence
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: G01N 2800/224 Haemostasis or coagulation
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors
• CPC Class Codes: Y10T 428/24496 Foamed or cellular component

Abstract

The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof. The present invention also relates to novel hemostatic foam substrates, a method of manufacturing the foam substrates, and a method of stimulating hemostasis in a mammal using such foam substrates.

Claims

1. A method of making a hemostatic foam substrate, comprising the steps of:

preparing a 3 weight % solution of 35/65 (mol/mol) PCL/PGA in 1,4-dioxane;

pouring the solution into a mold;

lyophilizing the solution in the mold;

adding an aqueous solution to the foam in the mold;

allowing the foam to soak in the aqueous solution at room temperature for a sufficiently effective period of time; and

,

lyophilizing the foam in the aqueous solution.

2. A hemostatic foam substrate prepared by the method of claim 1.

3. A method of enhancing hemostasis in a mammal comprising applying the foam substrate of claim 1 to a bleeding site on the mammal.

4. The hemostatic foam substrate of claim 1 comprising a 35/65 (mol/mol) PCL/PGA.